Vertex Pharmaceuticals (NASDAQ: VRTX) has proven itself to be an excellent long-term investment, advancing 91% over the past ...

Vertex Pharmaceuticals (VRTX) has quietly added to recent gains, with shares up around 10% over the past month and roughly 17 ...

Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Hey there! So, you want to keep an eye on how the big tech companies are doing, right? That’s where the US Tech 100 Index, ...

Vertex Pharmaceuticals has seen its fair value estimate inch up from about $480 to roughly $485 per share as analysts refresh ...

Major stock indexes ended higher for the seventh time in eight sessions Wednesday after initially declining following a poor private-payrolls reading and a report that Microsoft is cutting AI software ...